PRIMOVIST Solution for injection Ref.[9494] Active ingredients: Gadoxetic acid

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Bayer plc, 400 South Oak Way, Reading, RG2 6AD

Product name and form

Primovist 0.25 mmol/ml, solution for injection, pre-filled syringe.

Pharmaceutical Form

Solution for injection, prefilled syringe.

Clear, colourless to pale yellow liquid free from visible particles.

Qualitative and quantitative composition

Each ml contains 0.25 mmol gadoxetate disodium (Gd-EOB-DTPA disodium), equivalent to 181.43 mg gadoxetate disodium.

1 prefilled syringe with 5.0 ml contains 907 mg gadoxetate disodium,
1 prefilled syringe with 7.5 ml contains 1361 mg gadoxetate disodium,
1 prefilled syringe with 10.0 ml contains 1814 mg gadoxetate disodium.

Excipients with known effect: 11.7 mg sodium/ml.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Gadoxetic acid

Gadoxetic acid is a paramagnetic contrast agent for magnetic resonance imaging. The contrast-enhancing effect is mediated by gadoxetate (Gd EOB DTPA), an ionic complex consisting of gadolinium (III) and the ligand ethoxybenzyl-diethylenetriamine-pentaacetic acid (EOB-DTPA).

List of Excipients

Caloxetate trisodium
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Trometamol
Water for injections

Pack sizes and marketing

Glass syringes: 10 ml prefilled syringes consisting of a colourless siliconized PhEur type I glass barrel, a siliconized chlorobutyl elastomer plunger stopper, a chlorobutyl elastomer rubber tip cap, a polysulfone Luer Lock adapter and a polypropylene safety cap.

Plastic syringes: 10 ml prefilled syringes consisting of a colourless cycloolefin polymer plastic barrel with a thermoplastic elastomer tip seal, closed with a siliconized bromobutyl plunger.

Package sizes:

1, 5 and 10 × 5 ml (in 10 ml prefilled syringe)
1, 5 and 10 × 7.5 ml (in 10 ml prefilled syringe) (glass only)
1, 5 and 10 × 10 ml (in 10 ml prefilled syringe)

Not all pack sizes may be marketed.

Marketing authorization holder

Bayer plc, 400 South Oak Way, Reading, RG2 6AD

Marketing authorization dates and numbers

PL 00010/0555

Date of first authorisation: 10 November 2004
Date of renewal of the authorisation: 26 March 2014

Drugs

Drug Countries
PRIMOVIST Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Japan, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.